SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sean James Fallon, Katrijn Smulders, Rianne A. Esselink, Bart P. van de Warrenburg, Bastiaan R. Bloem, Roshan Cools, Differential optimal dopamine levels for set-shifting and working memory in Parkinson's disease, Neuropsychologia, 2015, 77, 42

    CrossRef

  2. 2
    Hayley J. MacDonald, Winston D. Byblow, Does Response Inhibition Have Pre- and Postdiagnostic Utility in Parkinson's Disease?, Journal of Motor Behavior, 2015, 47, 1, 29

    CrossRef

  3. 3
    Eleonora Džoljić, Ivana Novaković, Maja Krajinovic, Ivan Grbatinić, Vladimir Kostić, Pharmacogenetics of drug response in Parkinson's disease, International Journal of Neuroscience, 2015, 125, 9, 635

    CrossRef

  4. 4
    Caroline Moreau, Sayah Meguig, Jean-Christophe Corvol, Julien Labreuche, Francis Vasseur, Alain Duhamel, Arnaud Delval, Thomas Bardyn, Jean-Christophe Devedjian, Nathalie Rouaix, Gregory Petyt, Christine Brefel-Courbon, Fabienne Ory-Magne, Dominique Guehl, Alexandre Eusebio, Valérie Fraix, Pierre-Jean Saulnier, Ouhaid Lagha-Boukbiza, Frank Durif, Mirela Faighel, Caroline Giordana, Sophie Drapier, David Maltête, Christine Tranchant, Jean-Luc Houeto, Bettina Debû, Jean-Philippe Azulay, François Tison, Alain Destée, Marie Vidailhet, Olivier Rascol, Kathy Dujardin, Luc Defebvre, Régis Bordet, Bernard Sablonnière, David Devos, Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease, Brain, 2015, 138, 5, 1271

    CrossRef

  5. 5
    Weidong Ji, Ning Li, Kang Ju, Hong Zheng, Chuang Yang, Ping Xu, Silu Chen, Aiai Cao, Xue Chen, Lanting Guo, RETRACTED ARTICLE: Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients, Neurological Sciences, 2015, 36, 4, 561

    CrossRef

  6. 6
    Félix J. Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín, José A.G. Agúndez, COMT gene and risk for Parkinson’s disease, Pharmacogenetics and Genomics, 2014, 24, 7, 331

    CrossRef

  7. 7
    K. Dujardin, D. Devos, Genetic characterization of cognitive impairment in Parkinson's disease, Brain, 2014, 137, 10, 2630

    CrossRef

  8. 8
    C. Nombela, J. B. Rowe, S. E. Winder-Rhodes, A. Hampshire, A. M. Owen, D. P. Breen, G. W. Duncan, T. K. Khoo, A. J. Yarnall, M. J. Firbank, P. F. Chinnery, T. W. Robbins, J. T. O'Brien, D. J. Brooks, D. J. Burn, R. A. Barker, Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study, Brain, 2014, 137, 10, 2743

    CrossRef

  9. 9
    Brit Mollenhauer, Lynn Rochester, Alice Chen-Plotkin, David Brooks, What can biomarkers tell us about cognition in Parkinson's disease?, Movement Disorders, 2014, 29, 5
  10. 10
    David Devos, Caroline Moreau, Arnaud Delval, Kathy Dujardin, Luc Defebvre, Regis Bordet, Methylphenidate, CNS Drugs, 2013, 27, 1, 1

    CrossRef

  11. 11
    S.J. Fallon, A. Hampshire, C.H. Williams-Gray, R.A. Barker, A.M. Owen, Putative cortical dopamine levels affect cortical recruitment during planning, Neuropsychologia, 2013, 51, 11, 2194

    CrossRef

  12. 12
    Y. Kwak, N.I. Bohnen, M.L.T.M. Müller, P. Dayalu, D.T. Burke, R.D. Seidler, Task-dependent interactions between Dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease, Behavioural Brain Research, 2013, 245, 128

    CrossRef

  13. 13
    Monika Białecka, Mateusz Kurzawski, Anna Roszmann, Piotr Robowski, Emilia J. Sitek, Krystyna Honczarenko, Agnieszka Gorzkowska, Sławomir Budrewicz, Monika Mak, Monika Jarosz, Monika Gołąb-Janowska, Ewa Koziorowska-Gawron, Marek Droździk, Jarosław Sławek, Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s disease, Pharmacogenetics and Genomics, 2012, 22, 10, 716

    CrossRef

  14. 14
    Kathleen L. Poston, David Eidelberg, Functional brain networks and abnormal connectivity in the movement disorders, NeuroImage, 2012, 62, 4, 2261

    CrossRef

  15. 15
    James F. Morley, Sharon X. Xie, Howard I. Hurtig, Matthew B. Stern, Amy Colcher, Stacy Horn, Nabila Dahodwala, John E. Duda, Daniel Weintraub, Alice S. Chen-Plotkin, Vivianna Van Deerlin, Dana Falcone, Andrew Siderowf, Genetic influences on cognitive decline in Parkinson's disease, Movement Disorders, 2012, 27, 4
  16. 16
    Caroline Moreau, Arnaud Delval, Luc Defebvre, Kathy Dujardin, Alain Duhamel, Gregory Petyt, Isabelle Vuillaume, Jean-Christophe Corvol, Christine Brefel-Courbon, Fabienne Ory-Magne, Dominique Guehl, Alexandre Eusebio, Valérie Fraix, Pierre-Jean Saulnier, Ouhaid Lagha-Boukbiza, Frank Durif, Mirela Faighel, Caroline Giordana, Sophie Drapier, David Maltête, Christine Tranchant, Jean-Luc Houeto, Bettina Debû, Bernard Sablonniere, Jean-Philippe Azulay, François Tison, Olivier Rascol, Marie Vidailhet, Alain Destée, Bastiaan R Bloem, Régis Bordet, David Devos, Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial, The Lancet Neurology, 2012, 11, 7, 589

    CrossRef